[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia

Table 2

Comparison of baseline conditions in the use of rhTPO for treatment of grade II, III, and IV thrombocytopenia [n, (%)].

Characteristics	Use of recombinant human thrombopoietin (rhTPO)			χ^2/F value	P value
	Grade II (n = 100)	Grade III (n = 94)	Grade IV (n = 39)
Gender
Male	80 (80.0)	72 (76.6)	27 (69.2)	1.832	0.400
Female	20 (20.0)	22 (23.4)	12 (30.8)
Age (  ± s, years)	60.66 ± 8.47	62.84 ± 7.33	63.03 ± 7.20	2.337	0.099
Concurrent chemoradiotherapy
No	68 (68.0)	48 (51.1)	25 (64.1)	6.069	0.048
Yes	32 (32.0)	46 (48.9)	14 (35.9)